Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

Adds some spice to the discussion on the added value of prolonged IO post-operative

Can we shift the narrative from 'shared decision-making' to 'informed decision-making' so that the focus is where it should be - on patients/families being fully informed? Patients and families need all the information about treatment options to understand, ask the right

Don’t forget to sign up for BTOS2025 Belgian Respiratory Society belgianrespiratorysociety.be/nl/btos-2025

Now available in npj Journals Precision Oncology, results from the BALLETT molecular profiling study 🧬 🎯 using CGP & a national 🇧🇪 molecular tumor board. BALLETT is part of the Belgian Society of Medical Oncology PRECION program. 👏 Brigitte Maes & Pieter-Jan Volders Sciensano nature.com/articles/s4169…

Exciting news! Our abstract has been accepted for a poster presentation at the European Lung Cancer Congress (ELCC) 2025. We’re proud to share new data from our ongoing clinical development program with PDC*lung01, our therapeutic cancer vaccine NSCLC. lnkd.in/eMeKgmBn

🔬 Onze nieuwe CTC-website staat online! 💻 Medisch-wetenschappelijk onderzoek is essentieel voor betere zorg. Het Jessa Clinical Trial Center stimuleert, coördineert en ondersteunt onderzoeksactiviteiten binnen het ziekenhuis. Ontdek het hier 👉 jessazh.be/web/clinical-t…

📢 PDC*line Pharma at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. 🧬 Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1

#ASCO25 ASCO #NSCLC #LCSM TROPION-Lung04 Cohort 5 (Abstract 8521): 1L datopotamab deruxtecan + rilvegostomig in advanced/metastatic NSCLC without actionable genomic alterations: • 🎯 Confirmed ORR: 57.5% overall (62.1% non-squamous; 45.5% squamous) • 📊 Disease control

Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for. Grateful being involved and to our pts Just out in NEJM Presentation today by 1@only Charlie Rudin #ASCO25

More patients cured with neoadjuvant immunotherapy: CheckMate-816 OS now in #NEJM #ASCO2025

Results of Delphi-304 usher a new era for SCLC patients. Finally a truly game changer in the fight against this frightening disease. Immensely proud to have been part of this study. ASCO Jessa Ziekenhuis Jessa & Wetenschap Fac. Geneeskunde & Levenswetenschappen UHasselt Giannis Mountzios nejm.org/doi/full/10.10…

🔂The earlier the better? 🧪 Who needs more treatment? 🎯 How to improve cure? 👏👏👏👏 Lizza Hendriks #ASCO25

IMforte: RP3 maintenance lurbi+atezo ES-SCLC CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported. PFS HR=0.5: 2.1 to 5.5mo OS HR=0.73: 10.6 to 13.2mo (from randomztn) ORR 19.4 vs 10.4mo AEs as expected Bravo: a new standard of care #ASCO25

#ASCO25 Dr. Charlie Rudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, Amgen 🧪🔬🧬 science team and above all our pts

Another breakthrough for our SCLC patients! Based on personal experience, this regimen is well tolerated when properly managed. Proud that our site Jessa Ziekenhuis has yet again significantly contributed to a practice changing study. Jessa & Wetenschap Fac. Geneeskunde & Levenswetenschappen UHasselt

And let’s not forget the proportion of patients that don’t even get to therapy due to inadequate testing for AGAs or have no access to appropriate treatments

🫁 #ASCO2025 In-Depth! Dr Kristof Cuppens on SACHI : ✔️ Oral savolitinib + osi ✔️ PFS: 7–8 vs 4 mo vs chemo ✔️ Good tolerability 👀  Watch now bit.ly/4mLvOXR #MediMix #NSCLC #EGFR #MET

Phase III SAFFRON in EGFR+ NSCLC WITH MET-alteration post osi is still recruiting Jessa Ziekenhuis Jessa & Wetenschap Fac. Geneeskunde & Levenswetenschappen UHasselt Oncology at AstraZeneca